NMRA Neumora Therapeutics Inc: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

The market status of Neumora Therapeutics (NMRA) depends on the confirmed efficacy of its mental disorder therapy methods and the availability of R&D funding. This chart demonstrates an EPS of 27.40. The business relies on AI algorithms to develop drugs by processing massive datasets; however, current drug trials preclude profit growth, while laboratory maintenance leads to a constant capital outflow.
פילוחי מדדים פיננסיים ומדדי שוק עבור Neumora Therapeutics Inc (NMRA)

Year-over-year (YoY) EPS growth (TTM) measures the dynamics of net income per share over a rolling twelve-month period. By analyzing the current YoY TTM EPS growth rate, an investor assesses the speed of change in business profitability. This metric is sensitive to quarterly reporting, reflecting the efficiency of cost management. For Neumora Therapeutics (NMRA), this indicator demonstrates the financial flexibility of a full outsourcing model for production and clinical trials.